News

AddToAny

Google+ Facebook Twitter Twitter

Triple-negative breast cancer therapeutic target

Researchers have previously observed that triple-negative breast cancer (TNBC) patients with higher numbers of myeloid-derived immunosuppressor cells (MDSCs) in their bloodstream had poorer outcomes.

However, until now it wasn’t clear how MDSCs are recruited to the primary breast tumour and how they contributed to its progression and spread.

A new report fills in crucial details about the connection between MDSCs and aggressive disease.

Rumela Chakrabarti and colleagues identified a protein, deltaNp63, on tumour cells that directs MDSCs to the tumour and metastatic sites, where they promote tumour growth and metastasis.

Blocking this protein, or the MDSCs themselves, reduced tumour growth and metastasis in a mouse model of TNBC.

Chakrabarti said: “We’re excited because we think our findings could make a big difference for triple-negative breast cancer patient. Not only can deltaNp63 be used as a biomarker to help personalise treatment regimens, but targeting it may also provide an additive treatment for triple-negative breast cancer.”


Image credit | Science Photo Library 

Related Articles

War on cancer PT 1: the development of chemotherapy to 1950

A review of the early historical development and use of chemotherapy to treat different cancers. The phrase “war on cancer” refers to the recognition of cancer as a major cause of death and the need to act, resulting in increased funding, clinical trials and the development of more effective treatments.

3D human cell models

Medicines Discovery Catapult and the Medical Research Council Centre for Drug Safety Science at the University of Liverpool are collaborating.

Petition to ban sunbeds

A petition has been launched in the hope of persuading the government to ban commercial sunbeds in the UK.

My lab: cellular pathology

Consultant Cellular Pathologist Paul Cross gives a guided tour of his lab at the Queen Elizabeth Hospital, Gateshead Health NHS Foundation Trust.

Top